ASX Releases

2013

Notice of General Meeting/Proxy Form	June 17, 2013
s708 Cleansing Statement	June 14, 2013
Appendix 3B	June 14, 2013
US court decision positive for Benitec	June 14, 2013
R&D Tax Credit Received	June 13, 2013
NIH’s RAC gives favourable review of Benitec’s TT-034 for Hepatitis C	June 12, 2013
Capital Raising AUD7 Million Placement	June 6, 2013
Trading Halt	June 3, 2013
Benitec Selects CRO for European Lung Cancer Trial	June 3, 2013
s708 Cleansing Statement	May 29, 2013
Appendix 3B	May 28, 2013
Corporate Presentation May 2013	May 27, 2013
Pain Program Presentation at UK Conference	May 22, 2013
Update on General Meeting Timing	May 10, 2013
Appendix 4C - Quarterly	April 30, 2013
HCV clinical trial application submitted to RAC	April 17, 2013
UCSD selected as site for HCV Phase I/II trials	April 16, 2013
Benitec licensee secures orphan drug status	April 15, 2013
Initial Director's Interest Notice	April 12, 2013
Kevin Buchi Appointed to Benitec Board	April 11, 2013
Gene Silencing shows significant efficacy in vivo lung cancer model	April 4, 2013
Patent estate update	March 28, 2013
s708 Cleansing Statement	March 27, 2013
Appendix 3B	March 27, 2013
Further Capital Raising Completed	March 27, 2013
Duke Selected as site for Hep C Trials	March 22, 2013
Benitec China partner Biomics wins award	March 20, 2013
s708 Cleansing Statement	March 18, 2013
Appendix 3B	March 12, 2013
Hepatitis C clinical trial progress update	March 8, 2013
Completion of capital raising and proposed share capital consolidation	March 5, 2013
Half Yearly Report and Accounts	February 28, 2013
Appendix 4C - Quarterly	January 31, 2013
Benitec Presents at US-Based Investor Conferences	January 8, 2013
Corporate Presentation at Cappello US Investor Conference	January 8, 2013
Presentation at Cowen US Investor Showcase	January 8, 2013

2012

Benitec appoints CRO for Hepatitis C trial	December 18, 2012
UniQure licenses Benitec ddRNAi gene-silencing technology for Huntington’s treatment	December 4, 2012
Significant Gene Silencing Demonstrated in Benitec’s Muscular Dystrophy Program	December 4, 2012
BLT AGM Chairman's Address	November 16, 2012
High Delivery and Significant Gene-Silencing Demonstrated in Lung Cancer Program	November 13, 2012
Appendix 4C - Quarterly	October 31, 2012
Benitec Completes Acquisition of Tacere Therapeutics	October 30, 2012
ddRNAi – The New Therapeutic Revolutions? Benitec presents at Australian Microcap Investment Conference	October 17,2012
Benitec Acquires Tacere Hepatitis C Program	October 11, 2012
Benitec Biopharma's Hepatitis C patent granted in China	October 8, 2012
Benitec Biopharma Preliminary Final Report	August 28, 2012
Benitec teams with Stanford University on chronic pain research	August 13, 2012
Benitec and Medistem Demonstrate Value of ddRNAi in Preventing Heart Transplantation Rejection	July 30, 2012
Alnylam positive clinical results	July 18, 2012
Genable Technologies executes license agreement with Benitec Biopharma for a genetic eye disease retinitis pigmentosa	July 10, 2012
ddRNAi Drug for Hepatitis C Safe and Deliverable Reported in New Scientific Paper	June 28, 2012
Benitec Biopharma Announces the End of the Application for Revocation of UK Graham Patent	June 25, 2012
Benitec Biopharma detailed update on the progress with the Therapeutic Programs	June 19, 2012
Benitec Biopharma strengthens its executive management team	June 18, 2012
Calimmune License Announcement	March 5, 2012
Half yearly report and accounts to 31 December 2011	February 29, 2012
Clinical study confirms Benitec’s gene-silencing technology is safe and effective in Gradalis’ cancer vaccine	January 10, 2012
Pfizer and Tacrere Publish Pre-Clinical Results With Benitec’s ddRNAi	January 9, 2012

2011

Chief Investigators Group - Investor Presentation	November 18, 2011
Therapeutic Program Update	November 17, 2011
Chairman's Address AGM	November 17, 2011
Results of Annual General Meeting	November 17, 2011
Benitec Announces a New Therapeutic Program	October 31, 2011
Lead pain program to also target morphine intolerance	October 28, 2011
Appendix 4C - Quarterly	October 25, 2011
Patents Granted in US and Europe	October 24, 2011
Annual General Meeting Proxy Form	October 18, 2011
Notice of Annual General Meeting	October 18, 2011
Annual Report to Shareholders	October 18, 2011
Hepatitis program patents	October 6, 2011
European BioPartnering presentations	September 27, 2011
Pain Programme Update	September 19, 2011
Benitec's Appendix 4E and Full Year 2011 Statutory Accounts	Aug 24, 2011
Benitec Investor Newsletter	Aug 10, 2011
Change of Directors Interest Notice x4	Aug 10, 2011
Benitec Patent Estate Strengthened Further with Another Gene Silencing Graham Family Patent Allowed in the US	Aug 8, 2011
Benitec moves Operations to Sydney, replaces Chief Financial Officer	Aug 5, 2011
New Office Address and Contact Details	Jul 29, 2011
Appendix 4C Quarterly Cash Flow Update	Jul 29, 2011
Another Patent in Graham Family Allowed in US	Jul 27, 2011
Appendix 3B	Jun 30, 2011
Benitec's Pain Program Validated by Independent Study	Jun 20, 2011
Appendix 3B Partial Conversion	Jun 3, 2011
Notice of Initial Substantial Holder	Jun 1, 2011
Benitec's Gene Silencing Technology Used by Johns Hopkins' Scientists in the Development of a Treatment for Radio-Resistant Prostate Cancer	May 31, 2011
Appointment of Joint Company Secretary	May 26, 2011
Benitec granted another RNA Interference Patent in Japan: Further Expansion of the patent estate for the Hepatitis C Program	May 25, 2011
Benitec CEO's presentation to BioEquity Europe 2011	May 24, 2011
Top 20 Holders BLTOB Listed Options	May 20, 2011
Appendix 3B Correction	May 20, 2011
Renounceable Rights Issue - Share Allotment	May 19, 2011
Appendix 3B Renounceable Rights Issue	May 19, 2011
Benitec raises AU$8 million to Forge Ahead with its Gene Silencing Therapeutics: Rights Issue Closes Oversubscribed	May 17, 2001
Results of General Meeting	May 12, 2011
More patents granted in Europe and the US Significantly Strengthen Benitec’s Dominant Global Intellectual Property Position in Gene Silencing	May 4, 2011
Benitec Chosen to Present at BioEquity Europe 2011, May 23, Paris, France	May 4, 2011
Appendix 4C Quarterly Cash Flow Update	Apr 29, 2011
Despatch of Renounceable Rights Issue Documents	Apr 28, 2011
Appendix 3B Partial Conversion	Apr 18, 2011
Notice of General Meeting/Proxy Form	Apr 13, 2011
Letter to Overseas Shareholders	Apr 13, 2011
Letter to Australian & NZ Shareholders	Apr 13, 2011
Letter to Option Holders	Apr 13, 2011
Boardroom Radio Interview	Apr 12, 2011
Appendix 3B Rights Issue	Apr 11, 2011
Renounceable Rights Issue - Prospectus	Apr 11, 2011
Capital Raising and Changes to Capital Funding Arrangements	Apr 11, 2011
Change of Director's Interest Notice x2	Apr 7, 2011
Trading Halt	Apr 7, 2011
Options Update and Appendix 3B	Apr 4, 2011
Benitec Technology used by University of Queensland Scientists to Develop a Treatment for Cervical Cancer	Mar 29, 2011
Research Report on Benitec Released	Mar 24, 2011
RNAi Patent Update	Mar 22, 2011
Second US Clinical Study Using Benitec's ddRNAi Technology Announced	Mar 21, 2011
Becoming a Substantial Holder	Mar 11, 2011
Option Expiry Notice	Mar 3, 2011
Half Year Report and Appendix 4D	Feb 25, 2011
Hepatitis B RNAi Program Moves to the Next Stage	Feb 22, 2011
Formation of Chief Investigators Group	Feb 18, 2011
Patent Update: Strengthening and Expansion of Benitec's Dominant Patent Position in RNAi	Feb 17, 2011
Appendix 4C Quarterly Cash Flow Update	Jan 31, 2011
Appendix 3B and Cleansing Notice	Jan 24, 2011
Response to ASX Price Query	Jan 20, 2011
Appendix 3B CSIRO Top Up Shares	Jan 11, 2011
Release of Securities from Voluntary Escrow	Jan 10, 2011
Appendix 3B and Cleansing Notice	Jan 7, 2011